SY
Spyre Therapeutics, Inc.
SYRE · NASDAQ
$90.80 +0.22% (+$0.20)
1M -13.19%
Market Cap $7.89B
P/E Ratio -
Div. Yield -
ROE 24.32%
Bulios Fair Price
$62.91
30.7% downside
Current Price
$90.8
Undervalued Fair Value Overvalued
According to Bulios Fair Price, SYRE is currently overvalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Piotroski F-Score Weak
2/9Valuation
5 /100
Expensive P/B 7.16x
P/S 87.13x
EV/FFO N/A
Growth
100 /100
Growing Book val. growth 142.26%
FCF growth N/A
EPS growth N/A
Profitability
0 /100
Weak Op. margin 222.49%
Gross margin 0.00%
FCF margin 230.89%
Quality
1 /100
Poor ROA 15.25%
ROIC 18.14%
Asset turnover 0.08x
Debt
100 /100
Low Current ratio 18.53x
Debt/Equity 0.00x
Debt/Assets N/A
Stability
1 /100
Unstable Profitable years 0
Beta 3.00x
EPS volatility 91.50%
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about SYRE
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Cameron Turtle
Employees
125
Headquarters
Waltham
Upcoming events
03 NOV
Earnings
Upcoming earnings report